Welcome to LookChem.com Sign In|Join Free

CAS

  • or

856678-57-4

856678-57-4

Post Buying Request

856678-57-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

856678-57-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 856678-57-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,6,6,7 and 8 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 856678-57:
(8*8)+(7*5)+(6*6)+(5*6)+(4*7)+(3*8)+(2*5)+(1*7)=234
234 % 10 = 4
So 856678-57-4 is a valid CAS Registry Number.

856678-57-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 7-iodo-2,3-dihydro-1-benzofuran-5-sulfonyl chloride

1.2 Other means of identification

Product number -
Other names 5-Benzofuransulfonylchloride,2,3-dihydro-7-iodo

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:856678-57-4 SDS

856678-57-4Relevant articles and documents

ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS

-

Paragraph 00274, (2022/01/04)

Arylsulfonamides of carboxamido-piperidines, -pyrrolidines, and -azetidines, and their derivatives, are competitive and non-competitive inhibitors of the muscarinic acetylcholine receptor M5 (mAChR M5) and have utility in the treatment of psychiatric disorders such as substance-related misuse, substance- related disorder relapse, anxiety, depression, and psychosis.

NEW BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS .

-

Page/Page column 28, (2010/11/08)

The present invention relates to compounds of the general Formula (I), wherein R1, R2 and R3 are as defined in the description; to pharmaceutical compositions comprising these compounds; and to the use of the compounds for

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 856678-57-4